An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Cell
Liqin WangRene Bernards

Abstract

BRAF(V600E) mutant melanomas treated with inhibitors of the BRAF and MEK kinases almost invariably develop resistance that is frequently caused by reactivation of the mitogen activated protein kinase (MAPK) pathway. To identify novel treatment options for such patients, we searched for acquired vulnerabilities of MAPK inhibitor-resistant melanomas. We find that resistance to BRAF+MEK inhibitors is associated with increased levels of reactive oxygen species (ROS). Subsequent treatment with the histone deacetylase inhibitor vorinostat suppresses SLC7A11, leading to a lethal increase in the already-elevated levels of ROS in drug-resistant cells. This causes selective apoptotic death of only the drug-resistant tumor cells. Consistently, treatment of BRAF inhibitor-resistant melanoma with vorinostat in mice results in dramatic tumor regression. In a study in patients with advanced BRAF+MEK inhibitor-resistant melanoma, we find that vorinostat can selectively ablate drug-resistant tumor cells, providing clinical proof of concept for the novel therapy identified here.

Citations

Feb 21, 2019·Proceedings of the National Academy of Sciences of the United States of America·Romi GuptaNarendra Wajapeyee
May 7, 2019·Molecular Biology and Evolution·Gábor ApjokBálint Csörgő
Oct 5, 2019·Cancers·Mehwish Khaliq, Mohammad Fallahi-Sichani
Oct 12, 2019·Nature Reviews. Drug Discovery·Soufiane Boumahdi, Frederic J de Sauvage
Jan 17, 2020·Cells·Ufuk DegirmenciJiancheng Hu
Feb 23, 2020·PLoS Computational Biology·Natacha Comandante-LouMohammad Fallahi-Sichani
Dec 25, 2019·The Journal of Clinical Investigation·Kewen HuXiufeng Pang
May 14, 2020·Expert Opinion on Investigational Drugs·Laura Amanda BoosJames Larkin
Jan 11, 2020·Cell Death and Differentiation·Ishani DasUlrika Warpman Berglund
Jul 7, 2020·Molecular Systems Biology·Emanuel GonçalvesMathew J Garnett
Nov 30, 2018·The Journal of Experimental Medicine·Michela SerresiGaetano Gargiulo
Jul 20, 2018·Frontiers of Medicine·Liqin Wang, Rene Bernards
Oct 24, 2018·Biological Chemistry·Elena ObradorJosé M Estrela
Sep 29, 2020·Cancer Management and Research·Marta OsrodekMalgorzata Czyz
Mar 10, 2019·Biochemical Society Transactions·Ian J Majewski
Apr 21, 2019·International Journal of Molecular Sciences·Marc L SprouseDario Marchetti
Apr 23, 2020·Nature Communications·Ahmet AcarAndrea Sottoriva
May 3, 2020·Cellular and Molecular Life Sciences : CMLS·Anuradha KirtoniaManoj Garg
Oct 27, 2018·Frontiers in Oncology·Gaetano Gargiulo
Feb 13, 2020·International Journal of Molecular Sciences·Shannon LeeWalter Kolch
Jun 14, 2020·International Journal of Molecular Sciences·Balázs Zoltán Zsidó, Csaba Hetényi
Aug 28, 2020·Frontiers in Cell and Developmental Biology·Yue HuHui Wu
Jan 17, 2020·Antioxidants·Sahdeo Prasad, Sanjay K Srivastava
Jun 13, 2020·Frontiers in Oncology·Angelica AvaglianoAlessandro Arcucci
Dec 6, 2018·International Journal of Molecular Sciences·Malgorzata Czyz
Jun 7, 2018·Nature Reviews. Cancer·Sarah Seton-Rogers
Jan 21, 2019·Journal of Cancer Research and Clinical Oncology·Linlin WangYuanlin Song
Apr 3, 2020·International Journal of Oncology·Florencia Paula Madorsky RowdoJosé Mordoh
Nov 11, 2019·Journal of Experimental & Clinical Cancer Research : CR·Lihua WangTongke Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Cell eTOC

Cell is a scientific journal publishing research across a broad range of disciplines within the life sciences field. Discover the latest research from Cell here.

Related Papers

The New England Journal of Medicine
Keith T FlahertyJeffrey Weber
Molecular Cancer Therapeutics
Sharda JhaAhmed A Samatar
Molecular Cancer
Jaykumar ThumarHarriet M Kluger
© 2022 Meta ULC. All rights reserved